Business Description
NeuroBo Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US36870A1088
Description
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 110.52 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 82.2 | |||||
| 3-Year EPS without NRI Growth Rate | 80.9 | |||||
| 3-Year FCF Growth Rate | 76.2 | |||||
| 3-Year Book Growth Rate | -66.2 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.28 | |||||
| 9-Day RSI | 27.68 | |||||
| 14-Day RSI | 33.14 | |||||
| 6-1 Month Momentum % | 24.71 | |||||
| 12-1 Month Momentum % | -29.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.78 | |||||
| Quick Ratio | 3.78 | |||||
| Cash Ratio | 3.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -291.2 | |||||
| Shareholder Yield % | -0.86 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -58.99 | |||||
| ROA % | -43.48 | |||||
| ROIC % | -336.17 | |||||
| ROC (Joel Greenblatt) % | -12013.49 | |||||
| ROCE % | -58.83 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.01 | |||||
| Price-to-Tangible-Book | 1.01 | |||||
| EV-to-EBIT | 0.42 | |||||
| EV-to-EBITDA | 0.42 | |||||
| EV-to-FCF | 0.48 | |||||
| Price-to-Net-Current-Asset-Value | 1.03 | |||||
| Price-to-Net-Cash | 1.03 | |||||
| Earnings Yield (Greenblatt) % | 238.1 | |||||
| FCF Yield % | -64.29 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NRBO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
NeuroBo Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.38 | ||
| Beta | -0.25 | ||
| Volatility % | 95.06 | ||
| 14-Day RSI | 33.14 | ||
| 14-Day ATR ($) | 0.319751 | ||
| 20-Day SMA ($) | 3.89425 | ||
| 12-1 Month Momentum % | -29.17 | ||
| 52-Week Range ($) | 2.8888 - 6.7499 | ||
| Shares Outstanding (Mil) | 4.91 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NeuroBo Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NeuroBo Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
NeuroBo Pharmaceuticals Inc Frequently Asked Questions
What is NeuroBo Pharmaceuticals Inc(NRBO)'s stock price today?
The current price of NRBO is $3.44. The 52 week high of NRBO is $6.75 and 52 week low is $2.89.
When is next earnings date of NeuroBo Pharmaceuticals Inc(NRBO)?
The next earnings date of NeuroBo Pharmaceuticals Inc(NRBO) is 2024-05-10 Est..
Does NeuroBo Pharmaceuticals Inc(NRBO) pay dividends? If so, how much?
NeuroBo Pharmaceuticals Inc(NRBO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers